Atypical Hemolytic Uremic Syndrome (aHUS) Withdrawn Phase 2 Trials for Cemdisiran (DB16121)

Back to Atypical Hemolytic Uremic Syndrome (aHUS)

Also known as: Atypical Hemolytic Uraemic Syndrome / Atypical Hemolytic-Uremic Syndrome / Atypical Hemolytic Uremic Syndrome / Hemolytic-Uremic Syndrome, Atypical / Hemolytic Uremic Syndrome, Atypical / Atypical hemolytic uremic syndrome (disorder) / Atypical haemolytic uraemic syndrome / AHUS

IndicationStatusPhase
DBCOND0061539 (Atypical Hemolytic Uremic Syndrome (aHUS))Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03999840Eculizumab to Cemdisiran Switch in aHUSTreatment
NCT03303313A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic SyndromeTreatment